Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.

Subjects taking high potency opioid analgesics.

Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor.

Ongoing use of prohibited psoriasis treatments / medications.

Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα.

Previous treatment with any cell-depleting therapies.

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis